

ASX RELEASE
5 January 2018

**On-sale cleansing notice under section 708A(5)(e) Corporations Act –
Viralytics Limited (ASX Code: VLA)**

Viralytics Limited (**Viralytics**) has today issued 36,138,637 fully paid ordinary Viralytics shares at a price of \$0.82 to raise approximately \$29.6 million (**Shares**) by way of a placement to Lepu Medical Group, as outlined in Viralytics' announcement dated 5 January 2018.

Viralytics has issued the Shares without disclosure to investors under section 708(5) *Corporations Act 2001* (Cth) (**Corporations Act**).

Details of the securities issued

Class of securities:	Ordinary shares
ASX Code of the securities:	VLA
Date of the issue or expected issue of the securities:	5 January 2018
Total number of securities issued or expected to be issued:	36,138,637

For the purposes of section 708A(6) Corporations Act, Viralytics advises that:

- 1 (a) the Shares have been issued without disclosure to investors under Part 6D.2 Corporations Act;
- 2 (b) this notice is given under section 708A(5)(e) Corporations Act;
- (c) as at the date of this notice, Viralytics has complied with:
 - (i) the provisions of Chapter 2M Corporations Act as they apply to Viralytics; and
 - (ii) section 674 Corporations Act; and
- (d) as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) Corporations Act to be disclosed under section 708A(6)(e) Corporations Act.

Signed for and on behalf of Viralytics:



Sarah Prince
Company Secretary
Viralytics Limited

About Viralytics Ltd

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. The company's lead investigational product, CAVATAK[®], is currently being studied in clinical trials for the treatment of melanoma, as well as bladder and lung cancers. CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit www.viralytics.com.